SCHEMBL16362104

SCHEMBL16362104

CCc1cc2c(cc1-c1ccc(C(=O)Nc3c(F)cncc3F)cc1)N(C)C(=O)CO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 1/20 0.40
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ MAP3K5 Q99683 1/20 0.37
▸ GPR55 Q9Y2T6 1/20 0.37
▸ CHRM1 P11229 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.36
▸ ROCK2 O75116 3/20 0.35
▸ THRB P10828 1/20 0.35
▸ MGLL Q99685 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PDE3B Q13370 2/20 0.35
▸ PDE3A Q14432 2/20 0.35
▸ KLKB1 P03952 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.33
▸ HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16362060 0.96 PTGER3 (0.40) PTGER3CYP11B1CYP11B2MAP3K5GPR55
SCHEMBL16362059 0.86 PTGER3 (0.39) PTGER3CYP11B1CYP11B2MAP3K5GPR55
SCHEMBL16362422 0.84 PTGER3 (0.39) PTGER3CYP11B1CYP11B2MAP3K5GPR55
SCHEMBL19227409 0.80 STIM1 (0.35) ROCK2EGFR
SCHEMBL19227440 0.80 GPR55 (0.45) CYP11B1CYP11B2MAP3K5GPR55CHRM1
SCHEMBL16362447 0.78 IL2 (0.46) MAP3K5
SCHEMBL16362103 0.77 IL2 (0.48) PTGER3CYP11B1CYP11B2MAP3K5GPR55
SCHEMBL17766361 0.76 CYP11B2 (0.39) CYP11B2GPR55
SCHEMBL17766354 0.75 CYP11B2 (0.39) CYP11B2GPR55
SCHEMBL16335364 0.75 KDM4E (0.40) ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US claimed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US claimed
EP-3010586-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS Lupin Limited (IN) 2016-04-27 — — EP claimed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
WO-2014203217-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E PTGER3 287/4885CYP11B1 897/4885CYP11B2 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback